OMER - Omeros Corp Net Margin

Brandmark of Omeros Corp. (OMER)

Omeros Corporation generates revenue from OMIDRIA licenses and new immune developments, leveraging a diversified network of raw material suppliers. Demand analysis for transplant therapy within insurance funds and clinics underscores financial stability, confirming the level of revenue profitability. Meanwhile, the value of 132.30 reflects the metric's balance, allowing for the timely identification of fundamental risks or entry points into the asset.

Omeros (OMER) Net Margin: for the period 07/04/2022 - 11/20/2026

OMER (Omeros Corp): analytical breakdowns and indicator data

- market value and analyst target forecast:
Fundamental company valuation:Omeros - OMER
Flagship merchandise of Omeros

To protect capital from uncertainty, it is critical for investors to monitor the net profit margin, which reveals hidden cost growth. The laboratory diversification of Omeros Corporation (OMER) minimizes logistical risks, as reflected in the net profit margin as an indicator of the business's ability to convert operating activities into real income, ensuring long-term portfolio stability.

Competitors of Omeros Corporation (OMER)

BIIB: Net Sales Margin|Net Margin Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Corp) - Net Sales Margin|AXSM: Net Profit Rate|Net Margin acadia-pharm.com (ACAD)|Net Sales Margin Xenon Pharmaceuticals (XENE)|Net Margin Viking Therapeutics VKTX|Net Profit Rate SUPN|CPRX - Net Margin|Net Margin Denali Therapeutics|HRMY: Net Sales Margin|Biohaven - Net Profit Rate|Return on Sales by Net Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Company Sales Margin|Return on Sales by Net Profit PRAX (Praxis Medicines)|Anavex Corp - Net Return on Sales|Net Margin CeriBell CBLL|Company Sales Margin Prothena Biosciences (PRTA)|ALEC: Return on Sales by Net Profit|ANNX - Net Sales Margin|NGNE: Net Sales Margin|Return on Sales by Net Profit AC Immune|Return on Sales by Net Profit VYGR|Net Return on Sales NMRA (neumoratx.com)|Return on Sales by Net Profit SCLX (Scilex Holding Company, Inc.)|Net Margin TVGN (Tevogen Bio)|Net Margin Alpha Cognition ACOG|CGTX - Return on Sales by Net Profit|IKT - Net Margin|SAVA: Net Margin|Assertio Therapeutics (ASRT) - Net Margin|Net Margin Coya Therapeutics Inc (COYA)|Net Margin Vistagen|Net Return on Sales OVID (ovidrx.com)|Net Margin Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Net Margin|Alterity Therapeutics Ltd. - Return on Sales by Net Profit|CLNN - Return on Sales by Net Profit|PEPG - Net Margin|Company Sales Margin jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Net Margin|ANVS (Annovis Bio, Inc.) - Net Margin|Net Margin gracetx.com|Net Sales Margin Firefly Neuroscience, Inc.|Net Margin ANEW Medical (KLTO)|NRSN - Net Margin|Net Sales Margin RVPH (Reviva Pharmaceuticals Holdings Inc.)|Company Net Profitability MTVA (metaviatx.com)|NeurAxis Inc. - Net Sales Margin|Company Sales Margin heliusmedical.com HSDT|PASG: Net Sales Margin|Neuphoria - Net Profit Rate|Return on Sales by Net Profit NERV|ATHA: Net Profit Rate|Net Margin Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Net Profit Rate|Net Sales Margin CYCN (cyclerion.com)|Net Profitability Margin Protagenic|KTTA: Return on Sales by Net Profit|Net Profit Rate CRGT (cortigent.com)|ATXI: Net Sales Margin|BCLI (BrainStorm Cell Therapeutics) - Net Margin|CARA (Cara Therapeutics Inc.) - Net Sales Margin|Net Margin CHRO|Return on Sales by Net Profit ELYM (Eliem Therapeutics)|Net Margin ITCI (Intra-Cellular Therapies Inc.)|Net Sales Margin LBPH (Longboard Pharma)|Net Sales Margin Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - Net Sales Margin|Net Profit Rate NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Return on Sales by Net Profit|Net Return on Sales SNPX|Return on Sales by Net Profit TRVN|Net Margin VIGL|Net Sales Margin WENA|Company Sales Margin Cerevel